Rockefeller Capital Management
CRVS icon

Rockefeller Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Rockefeller Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,750
Closed -$1K – 2371
2022
Q4 		$1K Hold
1,750
– – ﹤0.01% 3660
2022
Q3 		$1K Hold
1,750
– – ﹤0.01% 3690
2022
Q2 		$1K Hold
1,750
– – ﹤0.01% 3925
2022
Q1 		$2K Hold
1,750
– – ﹤0.01% 3584
2021
Q4 		$4K Hold
1,750
– – ﹤0.01% 3335
2021
Q3 		$8K Sell
1,750
-750
-30% -$2.22K ﹤0.01% 2979
2021
Q2 		$6K Hold
2,500
– – ﹤0.01% 2961
2021
Q1 		$7K Buy
+2,500
New +$9.03K ﹤0.01% 2736

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Rockefeller Capital Management's CRVS Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2023, closing a stake of 1,750 shares — an estimated $1K sold.

Rockefeller Capital Management first reported a position in CRVS in Q1 2021 and held it in 8 quarters. The position peaked at $8K in Q3 2021. 37 funds tracked by Wall St. Rank hold CRVS as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Corvus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 1,750 Corvus Pharmaceuticals shares in Q1 2023, an estimated $1K.
  • Rockefeller Capital Management first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Rockefeller Capital Management's Corvus Pharmaceuticals position peaked at $8K in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.